Merck & Co Inc (NYSE:MRK)

57.60
Delayed Data
As of Apr 24
 +0.09 / +0.16%
Today’s Change
52.49
Today|||52-Week Range
63.62
+1.43%
Year-to-Date
If You Live in This State, You May Lose the Choice Whether to Vaccinate Your Kids
9:11am / MotleyFool.com
CAR-T Therapy Stocks Hit Hard Following AACR Data
Apr 20 / Benzinga
Are Biosimilars the Next Big Thing in Biotech?
Apr 25 / MotleyFool.com
Bristol-Myers combination melanoma treatment shows promise
Apr 20 / FT.com
Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
Apr 24 / Zacks.com
Morning Market Gainers
Apr 20 / Benzinga
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
Apr 24 / Zacks.com
Is Bristol-Myers Squibb. Co. About to Fall Apart?
Apr 20 / MotleyFool.com
The Parade of Weak Earnings Reports Continues - Earnings Preview
Apr 24 / Zacks.com
Best Pure Play Investment in Cancer Drugs
Apr 19 / MotleyFool.com
Market Wrap: Record Close for S&P
Apr 24 / TheStreet.com
Merck Seeks Expanded Approval of Keytruda Immunotherapy to Treat Lung Cancer
Apr 19 / TheStreet.com
Today's Top Performers In Drugs
Apr 24 / TheStreet.com
3 Drug Stocks Leading the Charge Against Infectious Diseases
Apr 18 / MotleyFool.com
AstraZeneca forced to defend cancer drug deal with Celgene
Apr 24 / FT.com
What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
Apr 18 / MotleyFool.com
Illumina's Earnings Set Positive Tone for Biotech
Apr 24 / MotleyFool.com
AstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog
Apr 16 / Zacks.com
Gilead May Be the Cure for the Blues
Apr 22 / TheStreet.com
The Best Stock to Invest in Hep C
Apr 16 / MotleyFool.com
Gilead May Be the Cure for the Blues
Apr 22 / TheStreet.com
Merck, NewLink Ebola Vaccine Enters Third Phase III Study - Analyst Blog
Apr 15 / Zacks.com
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
Apr 22 / MotleyFool.com
AstraZeneca's Onglyza Briefing Documents Raise Concern - Analyst Blog
Apr 13 / Zacks.com
Roche boosted by US drugs sales
Apr 22 / FT.com
3 Best Dividend Stocks in Healthcare
Apr 12 / MotleyFool.com
Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog
Apr 21 / Zacks.com
Biosimilar drugs: spot the difference
Apr 08 / FT.com
Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog
Apr 20 / Zacks.com
Big pharma turns to small biotechs for edge in cancer treatment
Apr 07 / FT.com
Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog
Apr 20 / Zacks.com
High price of gene therapy drug adds to costs debate
Apr 06 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account